Form 4: Apellis Pharmaceuticals Acquired by Biogen

Apellis Pharmaceuticals has been acquired by Biogen in a transaction valued at $41.00 per share plus a contingent value right.

Summary

• Apellis Pharmaceuticals, Inc. completed its merger with a subsidiary of Biogen Inc. on May 14, 2026.
• Shareholders receive $41.00 per share in cash plus one non-transferable contingent value right (CVR) per share.
• The CVR entitles holders to potential additional payments of up to $4.00 per share upon the achievement of specific milestones.
• All outstanding common stock was converted into the right to receive the offer price.
• Outstanding equity awards, including RSUs and stock options, were either cashed out, converted into contingent rights, or cancelled depending on their terms and exercise prices.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for shareholders, as the acquisition provides immediate liquidity at a set price with additional upside potential via CVRs.

Positives

• Shareholders receive a guaranteed cash payment of $41.00 per share.
• Potential for additional upside of up to $4.00 per share through contingent value rights (CVRs).
• Successful completion of the merger process as outlined in the March 31, 2026 agreement.

Negatives

• Stock options with an exercise price equal to or greater than $45.00 were cancelled without any consideration.
• The company ceases to exist as an independent publicly traded entity.

Risks

• The $4.00 per share CVR payment is contingent upon achieving specific milestones, which may not be met.
• The CVRs are non-transferable, limiting liquidity for holders.
• Payments are subject to applicable tax withholdings.

Future Outlook

The company has been acquired by Biogen and is now a wholly owned subsidiary; therefore, no independent future guidance is provided.

Management Comments

• The merger agreement dictates the conversion of all outstanding equity into cash and contingent rights.

Industry Context

StockSavvy.ai notes that this acquisition represents a significant consolidation in the biotechnology sector, with Biogen expanding its portfolio through the absorption of Apellis Pharmaceuticals.

Comparison to Industry Standards

• The use of CVRs in biotech acquisitions is a standard mechanism to bridge valuation gaps between buyers and sellers regarding pipeline assets.
• The $41.00 cash offer reflects the premium typically associated with mid-cap biotech buyouts.

Stakeholder Impact

• Shareholders receive cash consideration for their holdings.
• Employees and management are subject to the transition into Biogen's corporate structure.
• Creditors and suppliers will now deal with the surviving entity as a subsidiary of Biogen.

Next Steps

• Integration of Apellis Pharmaceuticals into Biogen operations.
• Monitoring of milestones related to the CVR agreement for potential future payouts.

Key Dates

Keywords

Apellis Pharmaceuticals, Biogen, Merger, Acquisition, APLS, Contingent Value Right, CVR